Finance

Lists
LXEO:NASDAQ
Lexeo Therapeutics Inc
$4.20
+0.48%
(+0.020) 1D
$4.20
0.00% (0.00)
After hours
Closed: Sep 18, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LXEO...
Open
$4.16
High
$4.22
Low
$4.06
Mkt. cap
344.59M
Avg. vol.
816.05K
Volume
2.29M
52-wk high
$10.99
52-wk low
$3.99
EPS
-$1.16
Shares outstanding
82.05M
No. of employees
63
Open
$4.16
High
$4.22
Low
$4.06
Mkt. cap
344.59M
Avg. vol.
816.05K
Volume
2.29M
52-wk high
$10.99
52-wk low
$3.99
EPS
-$1.16
Shares outstanding
82.05M
No. of employees
63
News stories
From web sources and news partners
About Lexeo Therapeutics Inc
CEO-
Employees63
Founded2017
Headquarters-
SectorBiotechnology
Websitelexeotx.com
Analyst ratings
Based on 3 analysts giving stock ratings to LXEO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for LXEO in the last 3 months.
Highest
Current $4.20
$20.00 (+376.19%)
Average
$15.33 (+265.00%)
Lowest
$9.00 (+114.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luca Issi
RBC Capital
Buy
Maintained
$20.00
+376.2%
08/12/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$17.00
+304.8%
07/06/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
$9.00
+114.3%
06/25/2026
Unknown Analyst
Stifel Nicolaus
Buy
Maintained
$17.00
+304.8%
05/12/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$17.00
+304.8%
05/11/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$20.00
+376.2%
03/31/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$19.00
+352.4%
03/30/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$10.00
+138.1%
01/13/2026
Christopher Raymond
Raymond James
Buy
Maintained
$25.00
+495.2%
01/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
15.70M
16.21M
15.70M
19.03M
Cost of revenue
15.70M
16.21M
15.70M
19.03M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.95M
6.91M
6.63M
8.99M
Operating expense
5.95M
6.91M
6.63M
8.99M
Total operating expenses
21.65M
23.12M
22.33M
28.02M
Operating income
-21.65M
-23.12M
-22.33M
-28.02M
Other non operating income
-9.00K
9.00K
-1.00K
-6.00K
EBT including unusual items
-20.28M
-20.92M
-20.20M
-25.87M
EBT excluding unusual items
-20.22M
-20.91M
-20.24M
-25.85M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.28M
-20.92M
-20.20M
-25.87M
Net profit margin
-
-
-
-
Earnings per share
-0.33
-0.27
-0.25
-0.30
Interest and investment income
1.46M
2.21M
2.11M
2.19M
Interest expense
-22.00K
-20.00K
-17.00K
-14.00K
Net interest expenses
1.43M
2.19M
2.10M
2.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.50M
-22.96M
-22.18M
-27.87M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps